{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:01:15Z","timestamp":1787169675271,"version":"build-2736575974"},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2019,9,1]]},"abstract":"<jats:p>\n                    <jats:bold>SETTING:<\/jats:bold>\n                    Data were collected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon.\n                    <jats:bold>OBJECTIVE:<\/jats:bold>\n                    To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin\n (LVX) based STR on bacteriological effectiveness.\n                    <jats:bold>DESIGN:<\/jats:bold>\n                    Retrospective study of prospectively collected data.\n                    <jats:bold>RESULTS:<\/jats:bold>\n                    Among 1530 patients, bacteriological effectiveness was 96.7% overall. Stratified by treatment with a GFX-, LVX- or MFX-based regimen effectiveness was\n respectively 97.5%, 95.5% and 94.7%. Compared to those on a GFX-based regimen, the estimated summary odds ratio of having an adverse outcome was more than double (OR 2.05, 95% CI 1.09\u20133.90) in patients treated with either an LVX-based or MFX-based regimen. After adjusting for initial\n resistance, patients treated with an LVX-based regimen and MFX-based regimen had respectively a 4.5- and 8.4-fold times larger odds of an adverse bacteriological outcome. None among 859 patients at risk treated with a GFX-based compared to at least 4 of 228 among those on an MFX-based regimen\n acquired fluoroquinolone resistance.\n                    <jats:bold>CONCLUSION:<\/jats:bold>\n                    GFX-based regimens had superior bacteriological effectiveness than MFX-based or LVX-based regimens. As GFX is currently unavailable in most MDR-TB programs, its reintroduction should be prioritised.\n                  <\/jats:p>","DOI":"10.5588\/ijtld.19.0053","type":"journal-article","created":{"date-parts":[[2019,10,16]],"date-time":"2019-10-16T00:37:59Z","timestamp":1571186279000},"page":"965-971","source":"Crossref","is-referenced-by-count":28,"title":["Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB"],"prefix":"10.5588","volume":"23","author":[{"given":"A.","family":"Van Deun","sequence":"first","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decroo","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Institute of Tropical Medicine, Antwerp, Research Foundation Flanders, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Kuaban","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, University of Bamenda, Bamenda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Noeske","sequence":"additional","affiliation":[{"name":"Independent Consultant, Douala, Cameroon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Piubello","sequence":"additional","affiliation":[{"name":"International Union Against Tuberculosis and Lung Disease, Paris, France, Damien Foundation, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. J. M.","family":"Aung","sequence":"additional","affiliation":[{"name":"Damien Foundation Bangladesh, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. L.","family":"Rieder","sequence":"additional","affiliation":[{"name":"Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Tuberculosis Consultant Services, Kirchlindach, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2019\/00000023\/00000009\/art00002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,29]],"date-time":"2019-10-29T04:44:55Z","timestamp":1572324295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.19.0053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,1]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9,1]]}},"alternative-id":["1027-3719(20190901)23:9L.965;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.19.0053","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,1]]}}}